Statins and Congestive Heart Failure

Overview

Journal Curr Atheroscler Rep

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2008 Aug 19

PMID 18706277

Authors

Jennifer Martin

Affiliations

Soon will be listed here.

Abstract

Despite many post hoc analyses of cardiovascular databases in recent years suggesting a benefit of statins in the prevention and treatment of congestive heart failure (HF), a prospective study of statin therapy on two clinically relevant end points--HF morbidity and survival--had not been reported until 2007. However, a large-scale prospective trial, Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA), has just reported its primary results. These results somewhat surprisingly show no survival benefit in a group of patients with ischemic systolic HF given low-dose rosuvastatin. In addition to this uncertainty generated by the results of CORONA, there remains additional uncertainty in the existing, predominantly retrospective data on statins because of the potential bias in study designs, use of post hoc subgroup analyses, and lack of mechanistic data. This review critically evaluates the recent literature in this area.

References

Go A, Lee W, Yang J, Lo J, Gurwitz J . Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA. 2006; 296(17):2105-11. DOI: 10.1001/jama.296.17.2105. View

Oi S, HANEDA T, Osaki J, Kashiwagi Y, Nakamura Y, Kawabe J . Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol. 1999; 376(1-2):139-48. DOI: 10.1016/s0014-2999(99)00282-4. View

Horwich T, MacLellan W, Fonarow G . Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol. 2004; 43(4):642-8. DOI: 10.1016/j.jacc.2003.07.049. View

Ridker P, Rifai N, Pfeffer M, Sacks F, Braunwald E . Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999; 100(3):230-5. DOI: 10.1161/01.cir.100.3.230. View

Sola S, Mir M, Rajagopalan S, Helmy T, Tandon N, Khan B . Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J Card Fail. 2005; 11(8):607-12. DOI: 10.1016/j.cardfail.2005.05.011. View

Khush K, Waters D, Bittner V, Deedwania P, Kastelein J, Lewis S . Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation. 2007; 115(5):576-83. DOI: 10.1161/CIRCULATIONAHA.106.625574. View

Cohn J, Johnson G, Shabetai R, LOEB H, Tristani F, Rector T . Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group. Circulation. 1993; 87(6 Suppl):VI5-16. View

Martin J, Krum H . Statins and clinical outcomes in heart failure. Clin Sci (Lond). 2007; 113(3):119-27. DOI: 10.1042/CS20070031. View

Martin J, Krum H . Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant?. Drug Saf. 2002; 26(1):13-21. DOI: 10.2165/00002018-200326010-00002. View

10.

Ruperez M, Lorenzo O, Blanco-Colio L, Esteban V, Egido J, Ruiz-Ortega M . Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation. 2003; 108(12):1499-505. DOI: 10.1161/01.CIR.0000089129.51288.BA. View

11.

Stumpf C, Lehner C, Yilmaz A, Daniel W, Garlichs C . Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. Clin Sci (Lond). 2003; 105(1):45-50. DOI: 10.1042/CS20020359. View

12.

Hasegawa H, Yamamoto R, Takano H, Mizukami M, Asakawa M, Nagai T . 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol. 2003; 35(8):953-60. DOI: 10.1016/s0022-2828(03)00180-9. View

13.

Koch G, Benz C, Schmidt G, Olenik C, Aktories K . Role of Rho protein in lovastatin-induced breakdown of actin cytoskeleton. J Pharmacol Exp Ther. 1997; 283(2):901-9. View

14.

Rauchhaus M, Coats A, Anker S . The endotoxin-lipoprotein hypothesis. Lancet. 2000; 356(9233):930-3. DOI: 10.1016/S0140-6736(00)02690-8. View

15.

Laufs U, La Fata V, Plutzky J, Liao J . Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998; 97(12):1129-35. DOI: 10.1161/01.cir.97.12.1129. View

16.

Martin J, Denver R, Bailey M, Krum H . In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling. Clin Exp Pharmacol Physiol. 2005; 32(9):697-701. DOI: 10.1111/j.1440-1681.2005.04256.x. View

17.

Ezekowitz J, McAlister F, Humphries K, Norris C, Tonelli M, Ghali W . The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol. 2004; 44(8):1587-92. DOI: 10.1016/j.jacc.2004.06.072. View

18.

Joynt K, Gattis W, Hasselblad V, Fuzaylov S, Serebruany V, Gurbel P . Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. Am J Cardiol. 2004; 93(6):783-5. DOI: 10.1016/j.amjcard.2003.12.010. View

19.

Scirica B, Morrow D, Cannon C, Ray K, Sabatine M, Jarolim P . Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 2006; 47(11):2326-31. DOI: 10.1016/j.jacc.2006.03.034. View

20.

Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer D . The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000; 6(9):1004-10. PMC: 2828689. DOI: 10.1038/79510. View